Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review details the prevalence and management of ejaculatory disorders in men with benign prostatic hyperplasia-related urinary symptoms and highlights the importance of preserving peri-montanal tissue during treatment to maintain antegrade ejaculation.

Finasteride and dutasteride, used for prostate issues and hair loss, can cause side effects like sexual dysfunction and mental issues, which may continue even after stopping the medication, a condition called post-finasteride syndrome, for which there's currently no cure.

This review discusses the use of antiandrogens for various conditions like prostate cancer and highlights their potential benefits in remission rates and symptom improvement, but it reports no new clinical results.

This study found that dutasteride effectively improved urinary symptoms, reduced acute urinary retention risk, and decreased prostate volume in men with moderate to severe BPH over two years.

This review explores potential indications for prolactin receptor inhibitors beyond breast and prostate cancers, emphasizing the need for potent antibodies to further research prolactin receptor expression.

This review summarizes key characteristics of men's health issues such as erectile dysfunction and prostate cancer, along with specific nursing considerations, and reports no new research results.

This review found substantial data suggesting that heavy metals may influence tumor development and progression in cancers such as breast, lung, prostate, and gastric, though noted limitations and gaps in research data require further investigation.

This study in male rats found that Cernitin™ significantly relieved pain and decreased prostate weight in models of chronic prostatitis and benign prostatic hyperplasia, suggesting an anti-inflammatory effect.

This study found that SRD5A2 expression is absent in one third of benign adult prostates and is associated with hypermethylation, suggesting potential personalization of treatment for prostatic diseases based on methylation status.

In this study, researchers found that non-invasive analysis of skin surface lipid RNAs revealed alterations in gene expression patterns associated with atopic dermatitis, suggesting its potential for understanding skin disease pathophysiology.

This study discusses two cases of acneiform skin eruptions associated with the use of the EGFR inhibitor ZD1839 in prostate cancer treatment, emphasizing the need for dermatologists to be aware of potential skin reactions.

This research examined krill oil's effects on benign prostatic hyperplasia and found that it inhibited the growth of prostate cells in vitro and reduced prostate size and weight in a BPH rat model, suggesting potential as a prophylactic or therapeutic agent for BPH.

This study found that prenatal exposure to finasteride in rats disrupted male reproductive development, causing physical alterations such as delayed preputial separation and increased nipple retention.

This review discusses the molecular mechanisms of masculinization involving androgen signaling and their roles in male embryonic development and conditions like hypospadias and prostate cancer, and reports no clinical results.

This observational study provides cause-specific mortality estimates to help patients and physicians better understand long-term outcomes for localized prostate cancer based on initial treatment choices.

In this study, male rats exposed in utero to low-dose chemical mixtures had permanent reproductive tract alterations, suggesting additive effects even at doses below individual adverse levels.

This study found that men with Kennedy disease have a significantly lower risk of androgenetic alopecia, likely due to androgen receptor gene alterations from the disease's polyglutamine expansion.

This study found that multiple ion channel modulators, used here at clinical concentrations, increased intracellular calcium release in prostate and breast cancer cell lines.

This review discusses the role of steroid 5 alpha reductase 2 in converting testosterone to DHT and its association with conditions like benign prostatic hyperplasia and prostate cancer; it reports no new results.

In this study, researchers examined androgen receptor activity in the adult mouse brain and found specific expression in key brain areas, which could inform understanding of cognitive side effects in humans undergoing androgen deprivation therapy for prostate cancer.

This study reports that dutasteride, used alone or with tamsulosin, effectively reduces acute urine retention and surgery risk in men with benign prostatic hyperplasia, and may lower prostate cancer incidence, suggesting potential chemopreventive benefits.

This study demonstrated that derivatives of dehydroepiandrosterone (2a-b, 3a-f, and 4a-f) significantly reduced viable LNCaP prostate cancer cells, suggesting potential therapeutic use for metastatic prostate cancer, while finasteride did not alter cell viability.

In this study, short-term treatment with lovastatin showed no effect on symptom severity, prostate volume, or PSA levels in men with prostatic enlargement from presumed benign prostatic hyperplasia.

In this case report, treatment with antibiotics, finasteride, and prostate omentalization restored fertility in a 6-year-old German Shepherd with prostatitis and astenoteratozoospermia, avoiding surgical castration.

This review analyzes the potential mechanisms by which SARS-CoV-2 may exacerbate symptoms of benign prostatic hyperplasia and suggests a connection via ACE2 and androgen receptor pathways; it reports no new clinical results.

5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.

This study found that delmadinone acetate and finasteride caused a reversible suppression of prostate gland activity in male dogs, with delmadinone acetate also temporarily altering epididymal sperm maturation.

This study found that dutasteride was more effective than finasteride in reducing total prostate volume and PSA levels and improving symptoms in patients with benign prostate hyperplasia.

The authors reported that young men with infertility-related conditions experienced improved seminal quality after stopping finasteride, suggesting potential adverse effects on fertility during treatment.

This study describes a case where finasteride treatment for benign prostatic hypertrophy was associated with gynecomastia in a 62-year-old man, which resolved after the drug was discontinued.